Gro Gausdal

1.2k total citations
41 papers, 695 citations indexed

About

Gro Gausdal is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Gro Gausdal has authored 41 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Immunology, 23 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Gro Gausdal's work include Phagocytosis and Immune Regulation (27 papers), Pancreatic and Hepatic Oncology Research (17 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Gro Gausdal is often cited by papers focused on Phagocytosis and Immune Regulation (27 papers), Pancreatic and Hepatic Oncology Research (17 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Gro Gausdal collaborates with scholars based in Norway, United States and France. Gro Gausdal's co-authors include Stein Ove Døskeland, Bjørn Tore Gjertsen, James B. Lorens, Øystein Bruserud, Lars Herfindal, Emmet McCormack, David Micklem, Joël Vandekerckhove, Ingvild Haaland and Stian Knappskog and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Gro Gausdal

39 papers receiving 687 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gro Gausdal Norway 16 352 200 141 108 68 41 695
Giulia Porro Italy 6 574 1.6× 188 0.9× 152 1.1× 100 0.9× 25 0.4× 10 783
Beatriz Albella Spain 14 318 0.9× 255 1.3× 168 1.2× 256 2.4× 25 0.4× 31 803
Virginie Moucadel France 17 422 1.2× 114 0.6× 194 1.4× 81 0.8× 23 0.3× 26 934
Francesca Civoli United States 12 533 1.5× 133 0.7× 169 1.2× 43 0.4× 21 0.3× 20 735
Laia Rosich Spain 15 410 1.2× 121 0.6× 134 1.0× 69 0.6× 12 0.2× 21 721
Serdar Bedii Omay Türkiye 17 203 0.6× 48 0.2× 138 1.0× 149 1.4× 58 0.9× 41 611
Chaoxin Hu United States 13 434 1.2× 97 0.5× 367 2.6× 98 0.9× 19 0.3× 18 920
Gregg Timony United States 11 545 1.5× 142 0.7× 73 0.5× 78 0.7× 16 0.2× 24 882
Essam Ghazaly United Kingdom 15 421 1.2× 64 0.3× 274 1.9× 78 0.7× 124 1.8× 62 904
Rudolf Mihalik Hungary 16 535 1.5× 205 1.0× 206 1.5× 58 0.5× 28 0.4× 58 846

Countries citing papers authored by Gro Gausdal

Since Specialization
Citations

This map shows the geographic impact of Gro Gausdal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gro Gausdal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gro Gausdal more than expected).

Fields of papers citing papers by Gro Gausdal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gro Gausdal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gro Gausdal. The network helps show where Gro Gausdal may publish in the future.

Co-authorship network of co-authors of Gro Gausdal

This figure shows the co-authorship network connecting the top 25 collaborators of Gro Gausdal. A scholar is included among the top collaborators of Gro Gausdal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gro Gausdal. Gro Gausdal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jackson, Akil, et al.. (2024). Targeting AXL cellular networks in kidney fibrosis. Frontiers in Immunology. 15. 1446672–1446672. 1 indexed citations
2.
Tutusaus, Anna, Loreto Boix, María Reig, et al.. (2024). Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH. Frontiers in Immunology. 15. 1400553–1400553. 6 indexed citations
3.
Tenstad, Olav, et al.. (2024). In vivo turnover and biodistribution of soluble AXL: implications for biomarker development. Scientific Reports. 14(1). 16141–16141.
4.
Osman, Tarig, Fredrik Hoel, Tony Chen, et al.. (2021). Axl‐inhibitor bemcentinib alleviates mitochondrial dysfunction in the unilateral ureter obstruction murine model. Journal of Cellular and Molecular Medicine. 25(15). 7407–7417. 14 indexed citations
5.
Bohan, Dana, Kai J. Rogers, José A. Aguilar-Briseño, et al.. (2021). Phosphatidylserine receptors enhance SARS-CoV-2 infection. PLoS Pathogens. 17(11). e1009743–e1009743. 75 indexed citations
6.
Aesöy, Reidun, Øystein Bruserud, Annette K. Brenner, et al.. (2019). A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia. Molecular Cancer Therapeutics. 18(3). 567–578. 15 indexed citations
7.
Terry, Stéphane, Agnete S. T. Engelsen, Stéphanie Buart, et al.. (2019). AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity. Cancer Immunology Research. 7(11). 1789–1802. 61 indexed citations
8.
Tutusaus, Anna, Estefanía de Gregorio, Blanca Cucarull, et al.. (2019). A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target. Cellular and Molecular Gastroenterology and Hepatology. 9(3). 349–368. 50 indexed citations
9.
Straume, Oddbjørn, James B. Lorens, Gro Gausdal, Bjørn Tore Gjertsen, & Cornelia Schuster. (2019). A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma. Annals of Oncology. 30. v563–v563. 3 indexed citations
10.
11.
Hellesøy, Monica, Håkon Reikvam, Sonja Loges, et al.. (2016). Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. Blood. 128(22). 3995–3995. 1 indexed citations
12.
Aasebø, Elise, Marc Vaudel, Olav Mjaavatten, et al.. (2014). Performance of super‐SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. PROTEOMICS. 14(17-18). 1971–1976. 31 indexed citations
13.
Herfindal, Lars, et al.. (2013). Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. BMC Cancer. 13(1). 341–341. 2 indexed citations
14.
Nguyen, Éric, Gro Gausdal, Frédéric Pendino, et al.. (2013). Activation of Both Protein Kinase A (PKA) Type I and PKA Type II Isozymes Is Required for Retinoid-Induced Maturation of Acute Promyelocytic Leukemia Cells. Molecular Pharmacology. 83(5). 1057–1065. 12 indexed citations
15.
Nygaard, Gyrid, Gro Gausdal, Håvard Sletta, et al.. (2013). Iodinin (1,6-Dihydroxyphenazine 5,10-Dioxide) from Streptosporangium sp. Induces Apoptosis Selectively in Myeloid Leukemia Cell Lines and Patient Cells. Marine Drugs. 11(2). 332–349. 27 indexed citations
16.
Jokela, Jouni, et al.. (2012). The lipopeptide toxins anabaenolysin A and B target biological membranes in a cholesterol-dependent manner. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1818(12). 3000–3009. 37 indexed citations
17.
Gausdal, Gro, T J Keen, Camilla Krakstad, et al.. (2011). Cyclic AMP induces IPC leukemia cell apoptosis via CRE-and CDK-dependent Bim transcription. Cell Death and Disease. 2(12). e237–e237. 21 indexed citations
18.
McCormack, Emmet, Ingvild Haaland, Gro Gausdal, et al.. (2011). Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 26(5). 910–917. 73 indexed citations
19.
Gausdal, Gro, et al.. (2004). Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. Leukemia. 18(12). 1989–1996. 31 indexed citations
20.
Gjertsen, Bjørn Tore, Anne M. Øyan, Bruz Marzolf, et al.. (2002). Analysis of Acute Myelogenous Leukemia: Preparation of Samples for Genomic and Proteomic Analyses. Journal of Hematotherapy & Stem Cell Research. 11(3). 469–481. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giulia Porro Breakdown of academic impact, for papers by Beatriz Albella Breakdown of academic impact, for papers by Virginie Moucadel Breakdown of academic impact, for papers by Francesca Civoli Breakdown of academic impact, for papers by Laia Rosich Breakdown of academic impact, for papers by Serdar Bedii Omay Breakdown of academic impact, for papers by Chaoxin Hu Breakdown of academic impact, for papers by Gregg Timony Breakdown of academic impact, for papers by Essam Ghazaly Breakdown of academic impact, for papers by Rudolf Mihalik
Rankless by CCL
2026